【参】六角形画像(Vision)
H1

Our Goal

コンテンツ

Top Message

It is with great pleasure that I wish you all a happy New Year. 

It is finally entering the 2020s.  This is the year of the Olympic and Paralympic Games Tokyo, and I hope it will be a year with full of bright topics.  Looking back at 2019, Japan national rugby union team showed a remarkable performance in the Rugby World Cup and I believe many of you got enthusiastic about the exciting matches.  It was really impressive that one sport won the hearts and minds of people.  I would like to see such scenes everywhere in the Olympics and Paralympic Games in Tokyo too.

In 2020, we, GTS, will promote R&D and business development for the realization of "GTS3.0" which has been advocated since 2018.  As part of this, GTS acquired Advanced Cell Technology and Engineering Ltd., last year, focusing on R&D  with SHED (stem cell from exfoliated deciduous teeth) for regenerative medicine use, in order to accelerate growth of our cell therapy business, which is one of our three core businesses.  We believe the application of SHED for therapeutic treatment is prominent, and will proceed with our business to deliver a treatment to patients at the earliest possible. 

In addition, GTS will steadily implement our biosimilar business, which builds our base to conduct cell therapy and the new biologic business.  Last year, we launched the second product in our biosimilar business.  We will continue to work to deliver our high-quality biosimilar products to patients and medical front. 

 In “GTS3.0”, we will focus on research and development of new drugs and treatments for pediatric, rare and intractable diseases.  We understand realizing this goal is not an easy step.   However, we will drive forward tenaciously our R&D activities this year to create  new solution for patients suffering from those diseases so that they could  play an active role in the society in the future. 

 

 We would appreciate your continued support! 

January, 2020

 Gene Techno Science
President & CEO
Masaharu Tani

Leadership Team to lead and execute GTS3.0 toward the success

コンテンツ

GTS3.0

Biotech Engineering Company, striving for value creation

Aiming at providing comprehensive healthcare solutions for patients as well as families and caregivers

Founded as a spin-out venture from Hokkaido University
Engaged in the research and development of new biologics and biosimilar products, and now striving for a new stage with cell therapy business

Start-up, IPO, Business Expansion

From Now On

For the Future

For the Future

Connecting advanced biotehcnologies existing in Japan,
and contributing to the brighter future for chirdren

Business Direction

Targeting diseases which has less accessibility for sufficient medical treatment, and exploring the new therapeutic area

Target Area

Pediatric disease (Including juvenile one), Orphan disease, Intractable disease, Asia-endemic disease

Our Mission

By applying the sophisticated biotechnologies

By applying the sophisticated biotechnologies, developing
credible products and services are essential for GTS to contribute to society across the world.

Brighter future for children

Declining birthrate and the aging population becomes a social
issue all over the world. It is no doubt that children and young people will be the generation to create next society. Important thing is for those young people to be able to live healthier and higher quality of life. Brighter future for children with our biotechnoloigies